Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;72(3):215-224.
doi: 10.1055/s-0031-1298320.

Breast Cancer: State of the Art and New Findings

C Melcher  1 , C Scholz  1 , B Jäger  2 , C Hagenbeck  1 , B Rack  2 , W Janni  1
Affiliations

Breast Cancer: State of the Art and New Findings

C Melcher et al. Geburtshilfe Frauenheilkd. 2012 Mar.

Abstract
in English, German

Advances in research have a highly influential role to play in the strategy of early detection, treatment and aftercare of breast cancer and therefore everyday clinical practice. Newly-defined prognosis factors and a new form of molecular subtype classification, for example, are intended to help identify patients who will actually benefit from chemotherapy. In the field of neoadjuvant chemotherapy, the inclusion of the angiogenesis inhibitor Bevacizumab and dual antiHER2 therapy is being discussed. What's more, where defined criteria are met, even with positive sentinel lymph nodes, axillary dissection is not performed; besides bisphosphonates RANKL antibody Denosumab is now an option in the treatment of bone metastases.

Die Fortschritte in der Forschung beeinflussen maßgeblich die Strategie der Früherkennung, Behandlung und Nachsorge des Mammakarzinoms und damit den klinischen Alltag. Neu definierte Prognosefaktoren sowie eine neue molekulare Subtypen-Klassifikation sollen helfen, Patientinnen zu identifizieren, die tatsächlich von einer Chemotherapie profitieren werden. Im Bereich der neoadjuvanten Chemotherapie werden die Hinzunahme des Angiogenesehemmers Bevacizumab und eine duale Anti-HER2-Therapie diskutiert. Zudem darf beim Vorliegen definierter Kriterien auch bei positivem Sentinellymphknoten auf eine Axilladissektion verzichtet werden, und bei der Behandlung ossärer Metastasen steht uns nun neben den Bisphosphonaten der RANKL-Antikörper Denosumab zur Verfügung.

Keywords: breast cancer; chemotherapy; endocrine therapy; molecular genetic subtypes; prognosis; radiotherapy; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest/Interessenkonflikt W. Janni obtains fee and unrestricted research grants by Sanofi-Aventis, Novartis, Pfizer, AstraZeneca, Wilex, Veridex, Amgen, Boehringer-Ingelheim. B. Rack obtains unrestricted research grants by AstraZeneca, Chugai, Lilly, Novartis, Sanofi-Aventis, Tosoh, Veridex. W. Janni erhält Honorare und uneingeschränkte Forschungszuschüsse von Sanofi-Aventis, Novartis, Pfizer, AstraZeneca, Wilex, Veridex, Amgen, Boehringer-Ingelheim. B. Rack erhält uneingeschränkte Forschungszuschüsse von AstraZeneca, Chugai, Lilly, Novartis, Sanofi-Aventis, Tosoh, Veridex.

References

    1. Goldhirsch A, Wood W C, Coates A S. et al.Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–1747. - PMC - PubMed
    1. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–322. - PubMed
    1. Untch M, Gerber B, Möbus V. et al.Zurich consensus: statement of German experts on St. Gallen conference 2011 on breast cancer (Zurich 2011) Geburtsh Frauenheilk. 2011;71:381–390.
    1. AGO-Empfehlungen Gynäkologische Onkologie – Kommission Mamma. Deutsche Version 11.1.0 http://www.ago-online.orglast access: 7.11.2011
    1. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006;33(3) 09:S9–S14. - PubMed